Skip to main content
Premium Trial:

Request an Annual Quote

Silicon Genetics Site Licenses GeneSpring to Karolinska Institute in Sweden

NEW YORK, April 24 – Silicon Genetics has licensed the latest version of its GeneSpring software to the Karolinska Institute of Sweden, the company said Tuesday.

GeneSpring, a desktop gene expression analysis software for microarray experiments, accepts data from array/scanner image analysis programs, other databases, spreadsheets, URLs, as well as UniGene, GenBank, and LocusLink databases. Silicon genetics just released version 4.0 at the beginning of the month.

"We are very pleased to have Karolinska Institute, Sweden's biggest science and medical research institution, choose our latest release of GeneSpring for their  microarray  experiment research efforts," said Andrew Conway, CEO of Silicon Genetics, in a statement. "Our customers are showing more interest in the site licensing option now that GeneSpring is a mature product in its fourth major release."

The parties did not disclose financial details of the agreement.

Silicon Genetics said that its current customers for GeneSpring and other products include 15 of the top pharma companies in the world, as well as 20 academic and agricultural institutions.

Recently, GeneLogic and Protogene signed agreements to co-distribute GeneSpring with their products.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.